$3.82
1.06%
Nasdaq, Nov 28, 10:10 pm CET
ISIN
US09203E1055
Symbol
BDTX

Black Diamond Therapeutics Inc Stock price

$3.82
-0.07 1.80% 1M
+1.83 91.96% 6M
+1.68 78.50% YTD
+1.25 48.64% 1Y
+1.65 76.04% 3Y
-29.52 88.54% 5Y
-35.66 90.32% 10Y
-35.66 90.32% 20Y
Nasdaq, Closing price Fri, Nov 28 2025
+0.04 1.06%
ISIN
US09203E1055
Symbol
BDTX
Industry

Key metrics

Basic
Market capitalization
$217.6m
Enterprise Value
$74.8m
Net debt
positive
Cash
$142.8m
Shares outstanding
57.0m
Valuation (TTM | estimate)
P/E
16.6 | 10.8
P/S
3.1 | 3.0
EV/Sales
1.1 | 1.0
EV/FCF
4.2
P/B
1.6
Financial Health
Equity Ratio
67.5%
Return on Equity
-84.3%
ROCE
4.0%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$70.0m | $71.4m
EBITDA
$6.3m | $14.5m
EBIT
$6.0m | $13.3m
Net Income
$14.0m | $20.2m
Free Cash Flow
$18.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
107.3% | 118.4%
EBIT
106.9% | 116.9%
Net Income
117.4% | 128.9%
Free Cash Flow
126.4%
Margin (TTM | estimate)
Gross
-
EBITDA
9.1% | 20.3%
EBIT
8.6%
Net
20.0% | 28.3%
Free Cash Flow
25.7%
More
EPS
$0.2
FCF per Share
$0.3
Short interest
16.0%
Employees
24
Rev per Employee
$0.0
Show more

Is Black Diamond Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Black Diamond Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Black Diamond Therapeutics Inc forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Black Diamond Therapeutics Inc forecast:

Buy
93%
Hold
7%

Financial data from Black Diamond Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
70 70
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 20 20
32% 32%
29%
- Research and Development Expense 45 45
22% 22%
64%
6.34 6.34
107% 107%
9%
- Depreciation and Amortization 0.34 0.34
8% 8%
0%
EBIT (Operating Income) EBIT 6 6
107% 107%
9%
Net Profit 14 14
117% 117%
20%

In millions USD.

Don't miss a Thing! We will send you all news about Black Diamond Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Black Diamond Therapeutics Inc Stock News

Positive
Seeking Alpha
10 days ago
Black Diamond Therapeutics remains undervalued despite recent share price gains, with a promising EGFR inhibitor pipeline targeting unmet needs. Silevertinib, BDTX's lead candidate, is advancing in NSCLC and glioblastoma, with key clinical updates expected in late 2025 and early 2026. BDTX's financial position is strong, with a cash runway extending into Q4 2027, supported by a recent $70 milli...
Neutral
GlobeNewsWire
24 days ago
CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., ar...
Neutral
GlobeNewsWire
24 days ago
CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update.
More Black Diamond Therapeutics Inc News

Company Profile

Black Diamond Therapeutics, Inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Head office United States
CEO Mark Velleca
Employees 24
Founded 2014
Website www.blackdiamondtherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today